Literature DB >> 9329679

The vasoactivity of A beta peptides.

F Crawford1, Z Suo, C Fang, A Sawar, G Su, G Arendash, M Mullan.   

Abstract

We have demonstrated that freshly solubilized A beta peptides can enhance vasoconstriction by phenylephrine or endothelin of isolated rat aorta. Concentrations of peptide producing these effects (100 nM-1 microM) are much lower than those requiring toxicity to endothelial cells in culture, and effects are immediate, not requiring the prolonged time periods for aggregation necessary in A beta cell culture toxicity experiments. Pre-treatment with SOD diminishes the enhancement of vasoconstriction by A beta peptides, suggesting that the effects are partly mediated via a decrease in the nitric oxide/superoxide ratio. Enhancement of endothelin vasoconstriction is observed with A beta 1-40 and A beta 1-42, but not with A beta 25-35 even at 5 microM, again suggesting the mechanism of A beta vasoactivity is distinct from that of A beta cytotoxicity. These observations raise the possibility that A beta peptides in contact with the cerebrovasculature could result in vasoconstriction, hypoperfusion and oxygen free radical imbalance contributing to the neurodegeneration of AD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9329679     DOI: 10.1111/j.1749-6632.1997.tb48459.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  7 in total

1.  Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis.

Authors:  R Lyle Patton; Walter M Kalback; Chera L Esh; Tyler A Kokjohn; Gregory D Van Vickle; Dean C Luehrs; Yu-Min Kuo; John Lopez; Daniel Brune; Isidro Ferrer; Eliezer Masliah; Amanda J Newel; Thomas G Beach; Eduardo M Castaño; Alex E Roher
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

2.  Midlife blood pressure, plasma β-amyloid, and the risk for Alzheimer disease: the Honolulu Asia Aging Study.

Authors:  Nilay S Shah; Jean-Sébastien Vidal; Kamal Masaki; Helen Petrovitch; G Webster Ross; Cathy Tilley; Ronald B DeMattos; Russell P Tracy; Lon R White; Lenore J Launer
Journal:  Hypertension       Date:  2012-03-05       Impact factor: 10.190

Review 3.  Phospholipase A2 and arachidonic acid in Alzheimer's disease.

Authors:  Rene O Sanchez-Mejia; Lennart Mucke
Journal:  Biochim Biophys Acta       Date:  2010-05-27

4.  Vitamin E but not 17beta-estradiol protects against vascular toxicity induced by beta-amyloid wild type and the Dutch amyloid variant.

Authors:  Francisco J Muñoz; Carlos Opazo; Gabriel Gil-Gómez; Gladys Tapia; Virginia Fernández; Miguel A Valverde; Nibaldo C Inestrosa
Journal:  J Neurosci       Date:  2002-04-15       Impact factor: 6.167

5.  Vascular amyloidosis impairs the gliovascular unit in a mouse model of Alzheimer's disease.

Authors:  Ian F Kimbrough; Stefanie Robel; Erik D Roberson; Harald Sontheimer
Journal:  Brain       Date:  2015-11-23       Impact factor: 13.501

6.  Neurochemical profile of dementia pugilistica.

Authors:  Tyler A Kokjohn; Chera L Maarouf; Ian D Daugs; Jesse M Hunter; Charisse M Whiteside; Michael Malek-Ahmadi; Emma Rodriguez; Walter Kalback; Sandra A Jacobson; Marwan N Sabbagh; Thomas G Beach; Alex E Roher
Journal:  J Neurotrauma       Date:  2013-06-01       Impact factor: 5.269

Review 7.  Methods to measure, model and manipulate fluid flow in brain.

Authors:  Krishnashis Chatterjee; Cora M Carman-Esparza; Jennifer M Munson
Journal:  J Neurosci Methods       Date:  2019-12-12       Impact factor: 2.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.